Literature DB >> 31250021

Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: A mini review.

Xiaowen Sun1, Tingyou Zhang1,2, Mengqian Li1, Limei Yin1, Jianxin Xue1.   

Abstract

Expression of Programmed Cell Death-1 (PD-1/CD279) on T cells and the ligand of PD-1, PD-L1 (CD274/B7-H1) on tumor cells or other immune cells, such as myeloid-derived suppressor cells, are important mechanisms to induce malignant immunosuppression. PD-1/PD-L1 expression on B cell subsets, as well as their signaling and inhibitory functions in solid tumors will be discussed in this review with the focus on how B cells expressing PD-1/PD-L1 play immunosuppressive roles in tumor progression, aiming to figure out the potential for development of diagnostic tools and new therapies involving this unique group of cells.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  B lymphocyte; Programmed cell death 1 receptor; programmed death ligand 1; tumor

Year:  2019        PMID: 31250021     DOI: 10.1093/qjmed/hcz162

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  10 in total

Review 1.  Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors:  Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal:  Biomedicines       Date:  2022-05-20

2.  PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles Downregulate PD-1 Expression by Macrophages and Inhibit Tumor Growth : PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles.

Authors:  Mahmoud S Hanafy; Stephanie Hufnagel; Andrea N Trementozzi; Wedad Sakran; Jeanne C Stachowiak; John J Koleng; Zhengrong Cui
Journal:  AAPS PharmSciTech       Date:  2021-01-31       Impact factor: 3.246

Review 3.  Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?

Authors:  Cinzia Solinas; Marco Aiello; Esdy Rozali; Matteo Lambertini; Karen Willard-Gallo; Edoardo Migliori
Journal:  Transl Oncol       Date:  2020-07-01       Impact factor: 4.243

Review 4.  Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer.

Authors:  Xiaowen Sun; Lu Gan; Aru Na; Lingling Ge; Baoqing Chen; Jiaming Liu
Journal:  J Oncol       Date:  2019-11-28       Impact factor: 4.375

5.  Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumab.

Authors:  Naoki Kadota; Nobuo Hatakeyama; Hiroyuki Hino; Michihiro Kunishige; Yoshihiro Kondo; Yoshio Okano; Hisanori Machida; Keishi Naruse; Tsutomu Shinohara; Shoji Sakiyama; Fumitaka Ogushi; Eiji Takeuchi
Journal:  Cancer Rep (Hoboken)       Date:  2021-11-24

6.  Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients.

Authors:  Jenny Pousette; Annelie Johansson; Carolin Jönsson; Tommy Fornander; Linda S Lindström; Hans Olsson; Gizeh Perez-Tenorio
Journal:  Cancers (Basel)       Date:  2022-10-04       Impact factor: 6.575

Review 7.  Immune Crosstalk Between Lymph Nodes and Breast Carcinomas, With a Focus on B Cells.

Authors:  Elena Alberts; Isobelle Wall; Dinis Pedro Calado; Anita Grigoriadis
Journal:  Front Mol Biosci       Date:  2021-05-28

8.  An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients.

Authors:  Shanshan Tang; Yiyi Zhuge
Journal:  Biomed Eng Online       Date:  2021-06-30       Impact factor: 2.819

Review 9.  Regulatory B cells in respiratory health and diseases.

Authors:  Madhvi Menon; Tracy Hussell; Halima Ali Shuwa
Journal:  Immunol Rev       Date:  2021-01-06       Impact factor: 10.983

10.  Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.

Authors:  Simona Serratì; Michele Guida; Letizia Porcelli; Amalia Azzariti; Roberta Di Fonte; Simona De Summa; Sabino Strippoli; Rosa Maria Iacobazzi; Alessandra Quarta; Ivana De Risi; Gabriella Guida; Angelo Paradiso
Journal:  Mol Cancer       Date:  2022-01-18       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.